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Although	cystic	fibrosis	(CF)	is	a	monogenic	disease,	its	clinical	manifestations	are	influenced	in	a	complex	
manner.	Severity	of	lung	disease,	the	main	cause	of	mortality	among	CF	patients,	is	likely	modulated	by	sev-
eral	genes.	The	mannose-binding	lectin	2	(MBL2)	gene	encodes	an	innate	immune	response	protein	and	has	
been	implicated	as	a	pulmonary	modifier	in	CF.	However,	reports	have	been	conflicting,	and	interactions	
with	other	modifiers	have	not	been	investigated.	We	therefore	evaluated	the	association	of	MBL2	with	CF	
pulmonary	phenotype	in	a	cohort	of	1,019	Canadian	pediatric	CF	patients.	MBL2	genotypes	were	combined	
into	low-,	intermediate-,	and	high-expression	groups	based	on	MBL2	levels	in	plasma.	Analysis	of	age	at	first	
infection	with	Pseudomonas aeruginosa	demonstrated	that	MBL2	deficiency	was	significantly	associated	with	
earlier	onset	of	infection.	This	MBL2	effect	was	amplified	in	patients	with	high-producing	genotypes	of	trans-
forming	growth	factor	beta	1	(TGFB1).	Similarly,	MBL2	deficiency	was	associated	with	more	rapid	decline	of	
pulmonary	function,	most	significantly	in	those	carrying	the	high-producing	TGFB1	genotype.	These	findings	
provide	evidence	of	gene-gene	interaction	in	the	pathogenesis	of	CF	lung	disease,	whereby	high	TGF-β1	pro-
duction	enhances	the	modulatory	effect	of	MBL2	on	the	age	of	first	bacterial	infection	and	the	rate	of	decline	
of	pulmonary	function.
Introduction
Cystic fibrosis (CF) is an autosomal-recessive disease typically 
manifesting with progressive obstructive lung disease, insufficien-
cy of the exocrine pancreas, and elevated electrolyte concentration 
in sweat glands (OMIM 219700). Although CF is a monogenic dis-
ease caused by mutations in the CF transmembrane conductance 
regulator (CFTR) gene, genotype-phenotype correlation studies of 
some manifestations suggest more complex inheritance, involving 
other genetic and environmental factors (1, 2). In particular, the 
severity of pulmonary disease, which is the major cause of morbid-
ity and mortality in CF, is poorly correlated with CFTR genotype. 
Patients carrying the same CFTR mutations show extremely vari-
able lung phenotypes at all ages. It is postulated that the severity 
and progression of pulmonary disease in CF is modulated by sec-
ondary genetic factors called CF modifiers (1, 3).
The hallmark of CF pulmonary disease is chronic infection with 
characteristic pathogens such as Pseudomonas aeruginosa, Staphylococ-
cus aureus, and Burkholderia cepacia, which leads to chronic inflam-
matory damage to lung tissue and progressive loss of pulmonary 
function. Genetic factors that influence susceptibility to infection 
are therefore of major interest. One of the first genes implicated 
as a pulmonary modifier in CF was the mannose-binding lectin 2 
(MBL2) gene (4). MBL2 produces a protein of the collectin family, a 
key factor in the innate immune response (5, 6). MBL2 selectively 
binds D-mannose and N-acetyl-D-glucosamine (GlcNAc) on bacte-
rial surfaces and triggers MBL2-associated serine proteases (MASPs), 
activation of the complement pathway, and eventual phagocyto-
sis of opsonized bacteria (7). MBL2 also regulates the secretion of 
cytokines: intermediate levels of MBL2 (1–5 μg/ml) trigger secre-
tion of proinflammatory cytokines (IL-6, TNF-α, and monocyte 
chemoattractant protein 1), while high levels of MBL2 (>6 μg/ml) 
are known to repress secretion of proinflammatory cytokines 
and upregulate the antiinflammatory cytokine IL-10 (8, 9). 
On the one hand, high levels of cytokines are beneficial because 
they initiate pathways necessary for clearing bacterial infection, but 
on the other hand, they can stimulate inflammatory cascades that 
are potentially detrimental to the lung tissue of CF patients (10).
MBL2 protein is known to bind to its substrates exclusively in an 
oligomerized form, and the collagen-like repeats are essential for the 
multimerization process. In the general population, levels of oligo-
merized MBL2 in blood vary dramatically (11), which is partially 
explained by genetic variation in MBL2. The rare X allele at position 
–221 of the promoter results in decreased promoter activity, while the 
missense mutations in exon 1 at positions 52, 54, and 57 in the colla-
gen-like domain abolish assembly of the protein into its biologically 
active form (12–14). It is well documented that low levels of MBL2 in 
the blood are associated with susceptibility to infections in various 
clinical settings (15, 16). Independent studies found 2-fold increase 
in childhood infections associated with MBL2 deficiency (17, 18).
In some studies of patients with CF, MBL2 deficiency has been 
associated with more severe pulmonary disease (4, 1–21) and 
poor survival (4, 22), while others have reported no association 
(23, 24). These studies were based on relatively small CF patient 
cohorts (about 100–300). A recent study of a large cohort of CF 
patients homozygous for the ΔF508 mutation found no associa-
Nonstandard	abbreviations	used: CF, cystic fibrosis; FEV1, forced expiratory vol-
ume in 1 s; PI, pancreatic insufficiency.
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tion between MBL2 variants and pulmonary function (25). The 
Drumm study was specifically designed to include age-specific 
extremes of pulmonary function, and patients under 8 years of age 
were excluded because of inability to define the severity of pulmo-
nary disease. This precluded the ability to test for potential effects 
of the MBL2 polymorphisms at an early stage of CF lung disease.
TGF-β1 is a growth factor that plays a critical role in inflamma-
tory processes likely to have pleiotropic effects in the lung. It pre-
vents spontaneous activation of alveolar macrophages and secre-
tion of proinflammatory cytokines and also causes inflammation, 
apoptosis, remodeling, and fibrosis of lung tissue, but does not 
affect the efficiency of phagocytosis (26–30). Several transforming 
growth factor beta 1 (TGFB1) gene variants were previously shown 
to affect the level of secreted protein (31, 32) and were reported 
to affect severity of lung disease in CF patients (25). Excessive tis-
sue fibrosis in CF lungs was proposed as the basis underlying the 
association of the high TGF-β1–producing allele C in codon 10 of 
the gene with severe pulmonary CF disease (25).
There were 3 main objectives of this study. The first was to evaluate 
MBL2 as a modifier of CF lung pathophysiology — represented by 
age of acquisition of P. aeruginosa and rate of decline of pulmonary 
function — in a large, representative sample of CF patients and to rec-
oncile different findings reported in previous studies (4, 19, 21, 25). 
The second was to examine the impact of another well-documented 
pulmonary CF modifier, TGF-β1 (25, 33), on these lung-related traits 
in young patients with CF disease. The final objective was to test for 
potential comodulation of both lung phenotypes by the MBL2 and 
TGFB1 genes and to analyze interactions between them.
Accordingly, CF patients in this study were recruited without 
selection bias and are representative of the general CF population 
in Canada (34). As the high variance of MBL2 concentrations in 
blood precluded effective grouping for our analysis, we turned to 
direct genotyping for the missense mutations and promoter poly-
morphism in the gene as our measurement of MBL2 activity. We 
also tested for potential gene-gene interactions between MBL2 and 
functional polymorphisms in the TGFB1 gene, which were report-
ed to modify the severity of pulmonary CF disease (25).
Our results showed that CF children with MBL2 deficiency 
acquired P. aeruginosa infection at a significantly earlier age and 
presented with more severe pulmonary disfunction 
than those with the intermediate or high levels of cir-
culating MBL2. We also demonstrated that these mod-
ulatory effects were enhanced by the high-producing 
TGFB1 gene variants, suggesting a complex gene-gene 
interaction between MBL2 and TGF-β1.
Results
Demographic and clinical characteristics of the pediatric 
CF patient cohort. The cohort of 1,019 CF pediatric 
patients is summarized in Table 1. The largest group 
of CF patients sharing the same CFTR genotype con-
sists of those homozygous for the ΔF508 mutation 
(35). This severely affected CF group serves as a 
clinical reference for patients with other CFTR geno-
types (36, 37). We compared the demographic and 
clinical parameters in CF patients homozygous for 
ΔF508 with the rest of the pancreatic insufficien-
cy (PI) group (Table 1). None of the demographic 
and clinical parameters were significantly different 
between the 2 groups.
MBL2 gene variants and genotypes. Four MBL2 gene variants (Table 2) 
were typed in 1,393 CF patients and 600 randomly selected parents 
from the entire CF Modifier Study cohort (see Methods). The dis-
tributions of these variants and related genotypes and diplotypes 
in patients and parents are shown in Supplemental Table 2 (sup-
plemental material available online with this article; doi:10.1172/
JCI33754). The overall allelic and genotypic frequencies were simi-
lar in the patient and parent cohorts and were not different from 
the previously published data (4, 11). We then established 6 major 
diplotypes from family members’ genotypes at 4 variant sites 
(Table 3); their frequencies were similar in patients and parents 
(Supplemental Table 2).
MBL2 protein levels in MBL2 diplotype groups. The plasma concen-
tration of oligomerized MBL2 protein was measured in the 1,393 
CF patients and 600 parents for whom the diplotypes had been 
established. As reported previously (11, 12), expression of MBL2 
oligomers and MBL2 genotypes were significantly correlated. The 
quantity of MBL2 protein in both the parent group (Figure 1A) and 
the CF patient group (Figure 1B) strongly correlated with the 6 dip-
lotype groups (Table 3). The normalized MBL2 expression increased 
with the proportion of A and Y alleles in these diplotypes, from **00 
to A0XY, A0YY, AAXX, AAXY, and AAYY (Figure 1). The functional 
consequences of structural mutations in exon 1 that prevent MBL2 
assembly (combined as the 0 allele) were more pronounced than 
the corresponding promoter variant X that is associated with lower 
MBL2 expression. This observation can be explained by the fact that 
homozygosity for any of the structural mutations or their com-
pound heterozygotes prevents oligomerization of MBL2 (14), while 
homozygosity for the X allele reduces production of the MBL2 oligo-
mer. However, considerable variation in expression was observed for 
various diplotypes, except for the **00 diplotype (Figure 1, A and 
B), where the presence of 2 structural mutations (denoted as 00) 
completely prevented oligomerization of MBL2 (14).
The lowest level of MBL2 expression in CF and parent cohorts 
was associated with 2 inferred diplotypes: **00 and XYA0. Pair-
wise analysis demonstrated that MBL2 expression was not statis-
tically different between individuals carrying the **00 and XYA0 
diplotypes. Therefore, the low MBL2 expression and MBL2-defi-
cient diplotype groups were combined to form the “low MBL2” dip-
Table 1
Demographic and clinical characteristics of CF patients (age <18.5 yr) with PI
	 All	patients	 By	CFTR	mutationA	 PB
	 	 ΔF508/ΔF508	 Other	PIC
nD 1,019 611 408
Mean age (yr) 10.5 10.5 10.5 0.94
Median age of diagnosis (yr) 0.36 0.35 0.38 0.35E
Meconium ileus 21.2% 22.3% 19.6% 0.35
CF liver disease 4.4% 3.8% 5.4% 0.22
CF-related diabetes 2.8% 2.9% 2.7% 0.85
Mean FEV1 % predicted 84.1% 83.7% 84.8% 0.50
P. aeruginosa positive 69.0% 67.3% 71.6% 0.15
Median age of first infection (yr) 7.2 7.5 6.9 0.13F
B. cepacia positive 5.5% 5.9% 4.9% 0.57
ACFTR mutations for patients in this cohort are listed in Supplemental Table 4. 
BΔF508/ΔF508 versus other PI; calculated by Student t test or Fisher exact test except 
where noted. CIncludes ΔF508/other and other/other severe genotypes. DExcept mean 
FEV1 % predicted (n = 801 total patients, 483 ΔF508/ΔF508, and 318 other PI). EWil-
coxon rank-sum test. FLog-rank test of time to event.
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lotype group (Table 4). Similarly, at the other extreme, the 2 dip-
lotypes corresponding to the highest expression, AAXY and AAYY, 
were combined into the “high MBL2” diplotype group (Table 4). 
The remaining 2 diplotypes demonstrating intermediate levels of 
MBL2 expression, including the rare XXAA diplotype (present in 
3.7% of patients) and the more common diplotype YYA0 (present 
in 25.8% of patients), were merged into an “intermediate MBL2” 
diplotype group (Table 4). The range of expression of the XXAA 
diplotype was similar to the range of the YYA0 diplotype, despite a 
significant difference in the median values (P < 0.0001).
MBL2 expression in CF patients and parents. Nonparametric analysis 
of the median normalized MBL2 expression between CF patients 
and the parent (control) group demonstrated that CF patients 
had significantly higher levels of MBL2 protein (Figure 1C 
and Supplemental Table 3). The higher MBL2 expression in CF 
patients was most likely associated with induction of MBL2 due 
to the persistent bacterial challenge and mobilization of innate 
defense mechanisms. The lack of significant elevation in MBL2 
expression in the **00 diplotypes almost certainly resulted from 
the structural mutations that prevent oligomerization of the pro-
tein which in turn leads to an inability to detect the MBL2 oligo-
mer in the assay system.
MBL2 expression in the pediatric and adult cohorts. To investigate a 
potential effect of age on MBL2 expression, the CF patients were 
divided into pediatric (age <18.5 yr; n = 848) and adult (age ≥18.5 
yr; n = 545) groups. The pediatric group had significantly higher 
plasma levels of MBL2 than the adult group for all diplotypes 
except **00 (Figure 1D).
MBL2 and age of first P. aeruginosa infection. Figure 2 shows the Kaplan-
Meier curves for the 3 MBL2 diplotypes in the pediatric cohort. The 
median age of first P. aeruginosa infection was significantly different 
for low, intermediate, and high MBL2 groups (4.4, 7.0, and 8.0 yr, 
respectively; P = 0.0003), indicating that MBL2 deficiency is associ-
ated with significantly earlier onset of P. aeruginosa infection.
Polymorphisms in the TGFB1 gene influence age of onset of first P. aerugi-
nosa infection in MBL2-deficient CF patients. High-expressing variants of 
TGFB1 have been shown to be associated with a more severe lung dis-
ease phenotype (25). To investigate whether this could be explained 
by early P. aeruginosa infection, we analyzed age of first infection 
for the TGFB1 codon 10 (rs1982073) genotypes in the pediatric CF 
cohort. There was no difference in the age of first P. aeruginosa infec-
tion between the genotypes (P = 0.7; Supplemental Figure 1).
Analysis of the MBL2 diplotype groups stratified by the TGFB1 
codon 10 genotypes demonstrated an influence of the high-express-
ing TGFB1 allele C on age of first P. aeruginosa infection among the 3 
MBL2 diplotype groups. No effect of MBL2 diplotype on age of first 
infection was observed in the subset of patients carrying the 
low-expressing TGFB1 genotype TT (P = 0.16; Figure 3A). 
However, in the subjects homozygous for the high-express-
ing TGFB1 C allele (CC genotype), the differences in median 
age of first P. aeruginosa infection by MBL2 diplotype group 
were magnified (low MBL2, 3.1 yr; intermediate MBL2, 
6.7 yr; high MBL2, 8.7 yr; P = 0.01; Figure 3C). In patients with 
low levels of MBL2, the CC genotype was associated with 
the earliest infection age, while the TT genotype was associ-
ated with the oldest age at first infection. The TGFB1 vari-
ant (rs2241715) exhibited a similar result as that observed 
for the codon 10 variant (data not shown). Although this 
observation suggested the possibility of gene-gene interac-
tion between MBL2 and TGFB1, testing by the Cox propor-
tional hazards regression model failed to detect such interaction 
(P = 0.2 for the interaction term MBL2*TGFB1).
MBL2 and MBL2/TGFB1 modulation of pulmonary function in CF 
patients. Of the patients studied, 511 were old enough to have 
multiple pulmonary function measurements in the 3 years before 
study enrollment. In a mixed regression model of forced expiratory 
volume in 1 s as a percentage of the predicted value (FEV1 % pre-
dicted; see Methods) versus age, MBL2, TGFB1, and all interaction 
terms, the 3-way interaction was significant (P = 0.002), indicating 
that the slope of FEV1 versus age was affected by MBL2 and TGFB1 
genotypes. Table 5 shows how the interaction of these modifiers 
affected lung function. Rate of decline of FEV1 was significantly 
steeper in the MBL2 diplotype group associated with low expres-
sion (P = 0.05). When stratified by TGFB1 genotype, the signifi-
cant effect of MBL2 on FEV1 was only seen in the high-expressing 
CC genotype group (P = 0.0002). The intercept at age 10 was rela-
tively stable across all genotype combinations, except in the high 
TGFB1/low MBL2 group, where it was significantly lower. Analy-
sis of TGFB1 codon 10 alone showed a significant effect on lung 
function, consistent with earlier reports. The rate of FEV1 decline 
was –2.62% (95% CI, –3.29% to –1.95%), –1. 22% (95% CI, –1.61% to 
–0.83%), and –2.04% (95% CI, –2.45% to –1.62%) per year in CC, CT, 
and TT genotypes, respectively (P = 0.0005), while the respective 
intercepts were 88.5%, 87.5%, and 86.3% (P = 0.7).
Taken together, these data suggest that the effect of MBL2 
expression is a critical determinant of the severity of lung disease 
at a young age in patients with CF disease and that high-express-
ing variants of TGFB1 enhance this effect. Age at first infection 
was a significant predictor of FEV1 intercept at age 10 (age <6 yr, 
Table 2
MBL2 gene variants and notation in the current study 
Variant	 Location	 Nucleotide	variant	 Amino	acid	change	 rs	no.
YA Promoter –221G – –
X Promoter –221C – 7096206
AA Exon 1 154C, 161G, 170G Arg52, Gly54, Gly57 –
BB Exon 1 154T Cys52 5030737
CB Exon 1 161A Asp54 1800450
DB Exon 1 170A Glu 57 1800451
AWild type. BDue to the same structural effect on the MBL2 protein, the B, C, and 
D variants were combined as the 0 variant group.
Table 3
MBL2 gene variants in this study: diplotypes 
Diplotype	 Predicted	genotype	 Simplified	
	 combinationsA	 notation
1 Y0/Y0 + X0/Y0 **00B
2C XA/Y0 XYA0
3 YA/Y0 YYA0
4 XA/XA XXAA
5 XA/YA XYAA
6 YA/YA YYAA
AThe phase prediction of the B, C, and D structural mutations (see Table 2)  
with the XY variant in the promoter region (–221) were based on the very 
high linkage disequilibrium between these mutations and Y allele of the XY 
variant. BThe extremely rare diplotype XY00 was combined with the YY00 
genotype as the **00 diplotype. CDiplotype 2 was inferred.
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82.2%, n = 161; age ≥6 yr, 89.3%, n = 350; P = 0.0001) but not of rate 
of decline (–1.95 and –1.72, respectively; P = 0.4). When infection 
age was added to the models of FEV1 versus MBL2 or TGFB1, both 
infection age and genotype remained significant predictors of lung 
function (data not shown).
Effect of gender on age at first infection and lung function. The age 
at first P. aeruginosa infection was significantly lower in females 
than in males (median age, 6.7 versus 7.9 years; P = 0.04, log-
rank test). However there was no interaction between gender and 
MBL2 diplotype group (P = 0.62) or TGFB1 codon 10 (P = 0.98) in 
a Cox regression model.
Consistent results were seen for lung function. Females 
showed a more rapid mean rate of decline in FEV1 than males 
(–1.45% versus –1.08% predicted per year; P < 0.0001), but there 
was a similar intercept at age 10 years (87.3% versus 86.7%; 
P = 0.73). Sex and the 3-way interaction of sex, age, and genotype 
were added to mixed models of FEV1 based on MBL2 or TGFB1, 
and there was no suggestion that the effects of either were dif-
ferent for males and females. The 3-way interaction terms were 
not significant in the MBL2 model (P = 0.80) or in the codon 10 
model (P = 0.41). The effect of gender on the interaction between 
TGFB1 codon10 and MBL2 diplotype groups for lung function 
decline could not be tested. This regression model involves a 
4-way interaction and all possible 2- and 3-way interactions, and 
the number of patients in the smallest categories of sex, MBL2 
group, and TGFB1 group were insufficient.
Figure 1
Normalized MBL2 levels corresponding to 6 MBL2 gene diplotypes (**00, XYA0, YYA0, XXAA, XYAA, and YYAA) in CF patient and parent 
cohorts. (A and B) Distribution of normalized MBL2 expression values and median MBL2 expression values for each diplotype is shown for 
600 parents (A) and 1,393 PI CF patients (B). (C and D) Comparison of normalized MBL2 expression values between patients and parents 
(C) and between 848 pediatric and 545 adult patients (D). Statistical difference was tested using the Wilcoxon rank-sum test. *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001.
Table 4
MBL2 gene variants in this study: diplotype groups  
Diplotype	combination	 Diplotype	group
Y0/Y0, X0/Y0, and XA/Y0 Low MBL2
YA/Y0 and XA/XA Intermediate MBL2 
XA/YA and YA/YA High MBL2
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MBL2 and age at first infection in ΔF508 homozygotes. Table 1 demon-
strates that lung function and age at first infection were similar in 
patients who were homozygous for the ΔF508 mutation and other PI 
patients. The effect of MBL2 on age at first infection was computed 
for this subset homozygous for ΔF508, and the results were consistent 
with the main analysis. The median age at first infection was 3.9 yr 
(95% CI, 2.9 to 9.7 yr), 7.4 yr (95% CI, 6.1 to 8.4 yr), and 8.1 yr (95% CI, 
7.2 to 9.2 yr) for low, intermediate and high MBL2 groups, respectively 
(P = 0.01, log-rank test). No further analysis was conducted on the 
subset of ΔF508 homozygotes because of the small subgroup sizes.
Figure 2
Results of time-to-event analysis showing median age and 95% CI 
at first positive culture for P. aeruginosa. The proportion of patients 
not infected with P. aeruginosa versus age is plotted for low MBL2 
(**00 and XYA0; n = 136), intermediate MBL2 (YYA0 and XXAA; 
n = 311), and high MBL2 (YYAA and XYAA; n = 572) diplotype 
groups. The graph shows data for 1,019 pediatric (<18.5 years of 
age) PI CF patients. Median age of infection was 4.4 yr (95% CI, 
3.2 to 6.4 yr) for the low MBL2 group, 7.0 yr (95% CI, 6.1 to 7.9 yr) 
for the intermediate MBL2 group, and 8.0 yr (95% CI, 7.2 to 8.8 yr) 
for the high MBL2 group. The survival probability differences were 
tested using log-rank test (P = 0.0003).
Figure 3
Results of time-to-event analysis (as in Figure 2) plotted for the 3 MBL2 diplotype groups and stratified by the codon 10 (rs1982073, L10P) 
TGFB1 genotypes. Data are shown for 1,003 pediatric PI CF patients; no codon 10 results were available for 16 patients. (A) For the TT genotype 
(n = 389), median age at first positive P. aeruginosa culture was 5.7 yr (95% CI, 2.4 to 9.7 yr) for the low MBL2 group (n = 56), 7.1 yr (95% CI, 
5.9 to 8.5 yr) for the intermediate MBL2 group (n = 115), and 7.4 yr (95% CI, 6.1 to 9.1 yr) for the high MBL2 group (n = 218). (B) For the CT 
genotype (n = 454), median age at first positive P. aeruginosa culture was 4.6 yr (95% CI, 3.5 to 9.7 yr) for the low MBL2 group (n = 53), 7.4 yr 
(95% CI, 5.9 to 8.9 yr) for the intermediate MBL2 group (n = 155), and 8.1 yr (95% CI, 7.1 to 9.4 yr) for the high MBL2 group (n = 246). (C) For 
the CC genotype (n = 160), median age at first positive P. aeruginosa culture was 3.1 yr (95% CI, 2.8 to 6.2 yr) for the low MBL2 group (n = 26), 
6.7 yr (95% CI, 3.4 to 9.1 yr) for the intermediate MBL2 group (n = 34), and 8.7 yr (95% CI, 7.1 to 10.4 yr) for the high MBL2 group (n = 100). 
Differences between groups were determined by the log-rank test.
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Discussion
Lung disease, the major life-limiting complication of CF, is poorly 
correlated with mutations in the disease-causing gene, CFTR (2). 
Emerging data from various studies of CF suggest a multifacto-
rial modulation of lung disease severity, including contributions 
of genetic, environmental, and stochastic factors (1). Studies of 
heritability of lung disease severity in CF demonstrated a sub-
stantial contribution of secondary genetic factors (38, 39). The 
estimated heritability of 0.68 is very high and indicates strong 
impact of secondary genetic component in controlling variation 
in CF lung disease severity (39). Although the number of pulmo-
nary CF modifiers is unknown, the relative contribution of sev-
eral genes can be inferred from current studies (25). For example, 
TGF-β1 is responsible for only 15%–20% of the variability in CF 
lung disease severity, suggesting involvement of additional modi-
fiers (25, 40). The complex inheritance of lung disease severity in 
CF may involve not only the contribution of multiple genes, but 
also interactions between them.
Our study thus offers insight into the complex genetics of CF 
modulation by demonstrating, for the first time to our knowledge, 
comodulation of traits related to CF lung disease by 2 genes, MBL2 
and TGFB1, as well as providing evidence for their interaction in 
controlling clinical variation of pulmonary phenotype in pediatric 
CF patients. We demonstrated that MBL2 deficiency was associ-
ated with a significant increase in the risk of early infection with 
P. aeruginosa and rate of decline of pulmonary function in pediatric 
CF patients. While polymorphisms in TGFB1 alone did not have an 
impact on age of acquisition of P. aeruginosa, we provided evidence 
that they significantly influenced its modulation by MBL2 and 
that the 2 genes interact to influence pulmonary function. Our 
results may explain apparently contradictory findings in previous 
reports, but replication of the combined gene effect would require 
a larger number of young patients than is available at present. 
Close follow-up of young patients in this and other cohorts will be 
necessary to confirm and refine the complex association.
The patient cohort was recruited from a population-based sam-
ple representing nearly 75% of the current Canadian CF population 
(34). The resource consists of DNA and plasma samples from CF 
patients and parents as well as demographic and clinical data from 
patients. Comparison with the Canadian CF Patient Registry dem-
onstrates that the demographic and clinical data in the recruited 
patient cohort were nationally representative (34). Consequently, the 
results obtained from these cohorts can be generalized to the entire 
Canadian CF population. Treatment and survival of CF patients 
has been steadily improving over the 2 decades in which the study 
patients were born. All analyses in this report were repeated, includ-
ing a binary birth cohort variable. In no case did birth cohort affect 
the results of MBL2 and TGFB1 genotypes (data not shown).
Secondary modulation of the severity of CF lung disease can be 
confounded by CFTR genotype, the primary determinant of disease 
severity. Patients carrying at least 1 mild CFTR mutation tend to 
have a milder form of CF (i.e., almost exclusively pancreatic suf-
ficiency). Pulmonary disease is somewhat milder, although highly 
variable, than in patients carrying severe mutations on both alleles 
(due to lack of CFTR protein synthesis, processing, or function). 
Therefore, to avoid a potential confounding effect of CFTR geno-
types, only pancreatic insufficient patients who had verified severe 
CFTR mutations on both alleles were included in this study. The 
demographic and clinical characteristics of the study population 
(Table 1) demonstrate that the subset of patients homozygous for 
the ΔF508 mutation were remarkably similar to the cohort patients 
carrying other severe CFTR genotypes, justifying the combination 
of the 2 patient groups as the study population for our analyses.
To our knowledge, this is the largest and most comprehensive 
study of MBL2 as a CF pulmonary disease modifier. We verified 
previous findings on the relationship between genotypes of the 
key MBL2 variants and expression of the MBL2 protein in periph-
eral blood (4, 12, 19). We also classified MBL2 diplotypes on the 
basis of plasma protein expression of oligomerized MBL2 and 
genotyped for the variants affecting production or assembly of 
Table 5
Mixed-model analyses of FEV1 % predicted versus age, MBL2 diplotype group, and codon 10 TGFB1 genotype in pediatric CF patients (<18.5 yr)
	 Low	MBL2	group	 Intermediate	MBL2	group	 High	MBL2	group	 P
All	patientsA	(n	=	511)
FEV1 %, 10 yr 85.1 87.4 87.2 0.70
Slope (95% CI) –2.57 (–3.3 to –1.8) –1.83 (–2.3 to –1.4) –1.56 (–1.9 to –1.2) 0.05
n 62 160 289
Codon	10	genotype	TT	(n	=	197)
FEV1 %, 10 yr 83.9 86.7 86.2 0.80
Slope (95% CI) –2.35 (–3.4 to –1.3) –1.56 (–2.3 to –0.8) –2.16 (–2.7 to –1.6) 0.36
n 30 61 106
Codon	10	genotype	CT	(n	=	233)
FEV1 %, 10 yr 87.2 85.8 88.5 0.65
Slope (95% CI) –1.00 (–2.4 to 0.4) –1.53 (–2.2 to –0.9) –1.09 (–1.6 to –0.6) 0.56
n 21 78 134
Codon	10	genotype	CC	(n	=	81)
FEV1 %, 10 yr 81.3 95.1 86.4 0.11
Slope (95% CI) –5.52 (–7.3 to –3.7) –3.47 (–4.8 to –2.2) –1.55 (–2.4 to –0.7) 0.0002
n 11 21 49
Shown are mixed-model estimates of mean FEV1 % predicted at 10 years of age and mean slope of FEV1 % predicted versus age. In a model based on age, 
TGFB1 codon 10 genotype, and MBL2 genotype group, there was a 3-way interaction (P = 0.002) of slope with MBL2 and TGFB1. Therefore, separate models of 
FEV1 versus age and MBL2 were computed for each TGFB1 codon 10 genotype. APatients with at least 2 measurements of FEV1 between 6 and 18 years of age.
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MBL2 protein (Table 2). Our results (Figure 1, A and B) confirmed 
earlier reports (4, 12, 19) showing a correlation between the 6 
MBL2 diplotypes and corresponding MBL2 expression levels. It 
should be noted, however, that there was considerable variation 
of MBL2 expression between subjects in each diplotype cohort. 
Other unspecified factors, such as unrecognized MBL2 mutations 
and modulation of MBL2 expression by disease factors, could 
account for the variable MBL2 expression levels (41).
Carlsson et al. (23) reported an increased plasma level of MBL2 
in CF patients. The results of the present study not only confirmed 
this observation, but also demonstrated that pediatric CF patients 
had significantly higher MBL2 plasma levels than adults. The 
higher MBL2 expression in pediatric CF patients could be attrib-
uted to an enhanced acute inflammatory response due to repeated 
bacterial challenge, which is not observed in older patients who 
have long-established chronic sinopulmonary infections.
In a previous study, Garred et al. (4) demonstrated an earlier 
age of onset of chronic P. aeruginosa infection in CF patients as a 
result of MBL2 deficiency. Because it is difficult to reliably estab-
lish the onset of chronic P. aeruginosa infection, we used age at the 
first positive respiratory culture as a surrogate. The time-to-event 
analysis showed that MBL2 deficiency was strongly associated 
with earlier acquisition of P. aeruginosa in young children with CF 
(P = 0.0003; Figure 2). This modulatory effect most likely reflects 
the critical role of MBL2 in the first defense against bacterial colo-
nization (16) and supports the similar but less significant effect 
previously observed in a small Italian CF patient cohort (42). How-
ever, it should be also noted that although MBL2 deficiency has 
been implicated in many studies as contributing to higher suscep-
tibility to infections, there are also data suggesting the opposite 
(43). This MBL duality may account for the relatively high fre-
quency of MBL variants encoding low MBL serum concentrations 
in some populations and should be seen in the context of specific 
circumstances of bacterial challenge and infection (43).
Notably, the MBL2-deficient patients carrying the high-express-
ing TGFB1 genotype CC had the most significant earlier onset of 
P. aeruginosa acquisition. Interestingly, although TGFB1 affected 
the modulation of age of onset by MBL2 in the pediatric patients, 
no direct impact of its codon 10 genotypes was observed in the 
time-to-event analysis using the same cohort unstratified for MBL2 
(Supplemental Figure 1). This modulation of the MBL2 effect by 
TGF-β1 could result from impaired bacterial eradication and clear-
ance in airways due to macrophage inactivation by elevated levels 
of TGF-β1 (44, 45). This, in conjunction with the MBL2 deficiency, 
would lead to the enhanced vulnerability of young CF patients 
to infection, manifesting as significantly earlier P. aeruginosa 
acquisition. This is in agreement with the well-documented dual 
role of TGF-β1 as a pro- and antiinflammatory cytokine in the 
immune defense system (46, 47).
Because CF children with MBL2 deficiency acquire P. aeruginosa 
pulmonary infections at a significantly younger age than those 
with normal levels, one might expect that MBL2-deficient children 
would have faster decline of pulmonary function. Indeed, as shown 
in Table 5, we demonstrated that MBL2 deficiency correlated with 
a more rapid rate of decline of pulmonary function. The observed 
effect could be explained by the recognized role of MBL2 in immu-
nity. Because MBL2 deficiency prevents the activation of the MBL2-
associated complement pathway, there is failure of the primary anti-
bacterial defense, namely macrophage phagocytosis of bacteria. In 
this regard, MBL2 is not only involved in innate antibacterial defense 
through the complement pathway, it is also a potent regulator of 
inflammatory pathways (9), which are highly dependent on the 
concentration of circulating MBL2. Low plasma MBL2 levels induce 
monocyte production of proinflammatory cytokines, whereas high 
MBL2 levels have a strong antiinflammatory effect (9). This observa-
tion provides a potential explanation for the magnified modulatory 
effect on the severity of lung disease in the MBL2-deficient children 
homozygous for the high-producing TGFB1 codon 10 variant C 
(P = 0.0002). Specifically, MBL2 deficiency (<4 μg/ml) has been 
shown to stimulate release of proinflammatory cytokines (TNF-α, 
IL-1B, and IL-6) from monocytes, whereas cytokine production is 
greatly suppressed with MBL2 levels higher than 6 μg/ml (9). The 
context of MBL2-induced high levels of proinflammatory cytokines 
could support activation of the TGF-β1–stimulated commitment of 
Th17 (i.e., IL-17–producing CD4+) T cell lineage producing neutro-
phil-mobilizing cytokines instrumental in the host defense to infec-
tions (46–49). In this situation, enhanced production of TGF-β1 
by the C allele could further inhibit the host defense by a variety 
of mechanisms. These include downregulation of macrophage 
receptors critical for phagocytosis (44, 50), downregulation of IgG 
receptors on monocytic cells, and reduction of phagocytosis of IgG-
opsonized bacteria (51) as well as other mechanisms critical for anti-
bacterial defenses, such as attenuation of innate immune signaling 
pathways mediated by TLR4 on LPS-induced macrophages (52).
The 2 clinical variables used in this analysis, namely the onset 
of lung infection and rate of decline of pulmonary function, have 
different contributions to CF lung pathophysiology. The first is a 
causative event, because lung infection is presumed to be an ini-
tiating event leading to progressive lung damage. The second is 
an outcome measure. Although the rate of decline of pulmonary 
function is clearly influenced by infection status, many other envi-
ronmental and genetic factors will have protective or deleterious 
consequences. In this regard, statistical modeling of gene-gene 
interactions between MBL2 and TGFB1 revealed strong interaction 
for lung function (P < 0.002) but not for the age of first P. aeruginosa 
infection (P = 0.2). Failure to detect MBL2/TGFB1 interaction for 
the infection variable may reflect the imprecision in assessment 
of first P. aeruginosa infection. Nevertheless, these results warrant 
investigation of the biochemical and physiological mechanisms of 
interaction between these 2 proteins.
Consideration should be given to the clinical implications of these 
findings. Genetic testing for MBL2 and TGFB1 variants may permit 
early identification of at-risk patients either at diagnosis or through 
newborn screening. This would allow physicians to closely moni-
tor these subjects and give consideration to more aggressive efforts 
to prevent early onset of bacterial infections. Knowledge of specific 
modifier genotypes would also permit more accurate patient strati-
fication for entry into therapeutic clinical trials. However, incorpo-
ration of genotyping into clinical trials and practice awaits deter-
mination of sensitivity and specificity for Pseudomonas prediction, 
ideally in a population of patients identified by newborn screening. 
Finally, recognition of the clinical consequences of MBL2 deficien-
cy may have therapeutic implications. For example, intravenous 
administration of human MBL2 derived from pooled plasma to an 
MBL2-deficient CF patient with end-stage lung disease was con-
sidered to have some beneficial effects (53). Nevertheless, our find-
ings suggest that success with MBL2 replacement therapy would 
require that it be administered prior to the onset of chronic bacterial 
infection. Now that recombinant MBL2 protein is available, there 
is wide interest in MBL2 supplementation. Trials are in progress 
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with recombinant MBL2 protein therapy in MBL2-deficient adults 
who are at increased risk of infection during chemotherapy or fol-
lowing liver or bone marrow transplantation (54, 55). A therapeutic 
trial with a recombinant MBL2 protein has also been proposed for 
MBL2-deficient CF patients (56). More research has to be done to 
refine the details of MBL2 modulation before seriously considering 
clinical trials of human recombinant MBL2 replacement therapy to 
delay or prevent early onset of chronic pulmonary infections in CF 
disease. However, MBL2-deficient patients may benefit from more 
frequent microbiological screening in order to detect earlier signs of 
infection that may respond to current antibiotic treatment.
In conclusion, based on its critical role in innate antibacterial 
defense, we postulate that MBL2 contributes to the variability of 
lung disease by modulating the age of acquisition of P. aeruginosa in 
pediatric CF patients. Furthermore, we provide evidence of a com-
plex interaction between MBL2 and TGF-β1 and rate of decline of 
pulmonary function in young patients with CF, possibly related to 
a synergistic effect on the onset of acquisition of P. aeruginosa infec-
tion. Gaining insight into the mechanisms of MBL2 modulation 
of lung pathophysiology in CF patients and its interaction with 
other pulmonary modifiers (e.g., TGF-β1) will be critical to explain 
our findings at a molecular level and provide a basis for developing 
modifier-based therapies.
Methods
CF patients and parent cohorts. CF patients and their family members were 
recruited from 37 specialized CF clinics across Canada (shown in Supple-
mental Table 5), during a period from 2003 to 2006, as participants in the 
Canadian CF Modifier Study. The protocols for this study were approved 
by ethical review boards at the Hospital for Sick Children and all partici-
pating institutions. Informed consent was obtained from each individual 
or his/her guardian. The Canadian CF Modifier Study population consists 
of 2,441 patients diagnosed with CF between 1951 and 2006 and 3,092 
parents. This report of first infection as a phenotype was restricted to pedi-
atric patients (<18.5 years of age at the time of recruitment) in order to 
capture the most reliable information on first infection and to compute 
average lung function decline unbiased by mortality selection. The age of 
first infection was generally not available in the records of patients report-
ed from clinics specializing in adult CF care. CF patients included in this 
study had PI and carried severe CFTR mutations on both alleles. Patients 
reported as PI but carrying at least 1 CFTR mutation typically associated 
with pancreatic sufficiency were excluded. The demographic and clinical 
characteristics of the pediatric patient cohort are shown in Table 1.
Pulmonary phenotypes. To evaluate MBL2 (and MBL2 stratified by TGF-β1 
variants) as a pulmonary CF modifier, 2 lung-related clinical outcome 
variables were used: age at first P. aeruginosa infection and FEV1. Patients 
attending Canadian CF clinics have sputum cultures and lung function 
testing at every clinic visit, which are routinely scheduled at 3-month inter-
vals. Age at the time of the first positive respiratory culture for P. aeruginosa 
was used as an indicator of susceptibility to infection with this bacterium. 
FEV1 (as percent of predicted for sex, height, and age) reflects the progres-
sion of CF lung disease and is the best predictor of survival (57). Predicted 
values were based on the formula of Knudson et al. (58) for those over 
the age of 10 years and Corey et al. (59) for those 6–10 years of age. FEV1 
measurements in the 3 years prior to enrollment were recorded in order to 
capture the current status and rate of decline for each patient.
Plasma and DNA samples. Individual blood samples were collected in glass 
tubes containing anticoagulant (Acid Citrate Dextrose, ACD-Vacutainer 
tubes; BD) and maintained at room temperature. Plasma samples were 
isolated by centrifugation at 524 g for 10 minutes and immediately frozen 
and stored at –70°C. Genomic DNA was extracted using the phenol/chlo-
roform procedure (60). The DNA stocks were stored at 4°C. Patients were 
recruited during the years 2003–2006, and the age in all analyses is based 
on the date the blood sample was taken.
Genotyping. For MBL2, 4 functional MBL2 gene variants were genotyped 
in genomic DNA samples: the promoter variant at position –221 (Y or X 
variant) and 3 structural mutations in exon 1 (B, C, and D variants), as 
shown in Table 2. The genotyping was performed using Luminex Bead 
Array technology (61, 62) implemented for the MBL2 variants as described 
in Supplemental Methods and Supplemental Table 1. MBL2 diplotypes 
(Table 3) were inferred from promoter variants X and Y and exon 1 struc-
tural variants A, B, C, and D according to Madsen et al. (11).
For TGFB1, the codon 10 expression variant (rs1982073, L10P) in TGFB1 
was genotyped using TaqMan genotyping assay (63). Genotyping of the 
promoter variant (–509; rs1800469) was performed using Luminex Bead 
Array technology (Luminex Corp.).
Measurement of MBL2 protein plasma levels. The plasma level of oligomer-
ized MBL2 protein was measured in blood samples from 1,393 CF patients 
and 600 parents as described in Supplemental Methods. The MBL2 pro-
tein levels were normalized to adjust for batch differences using the mean 
and standard deviation for 10 non-CF control samples included in every 
batch. Therefore the normalized MBL2 expression level reflects the varia-
tion above or below that expected for samples unrelated to CF.
Statistics. Patients who had not acquired P. aeruginosa infection at the time 
of observation will likely acquire the infection in the future; therefore, their 
age at first infection is unknown. To account for this, age at first infec-
tion was treated as a right-censored variable, and time-to-event analysis 
was used to compare age at first infection in different subgroups. Because 
infection is present for some unknown time before being cultured, the age 
at first positive culture is a left-censored estimate of true infection age. Left 
censoring is not considered in standard time-to-event analysis. Restriction 
of the study subjects to children and to those followed in specialized CF 
clinics minimizes the unknown time from infection to detection. We plot-
ted Kaplan-Meier survival curves to demonstrate the distribution of age at 
first P. aeruginosa infection, and curves were compared using the log-rank 
statistic. P. aeruginosa–free survival curves were compared for MBL2 geno-
type groups, for TGFB1 genotypes, and for MBL2/TGFB1 combinations. 
Cox proportional hazards regression was used to test the effects of sex and 
of multiple genotype groups on age at first infection.
Pulmonary function testing involves volitional breathing maneuvers that 
are generally not possible in children until 5–7 years of age. Data on cur-
rent lung function and decline over the past 3 years, represented by FEV1 
% predicted, were compiled for patients that had been tested. Longitudinal 
pulmonary function patterns (in patients with at least 2 measurements) 
were analyzed using a random effects mixed-model regression, as described 
by Schluchter et al. (64), and the mean intercept at 10 years of age and the 
mean slope were compared in potential modifier categories. The dependent 
variable in all models was FEV1 % predicted, and the time variable was age 
10 yr. Genotype groups for potential modifiers were included as categori-
cal variables. Interaction terms for modifier categories and age provided a 
statistical test for category differences in the change of lung function over 
time. The effects of gender and age at first infection were also added to 
selected models. Because age at first infection was censored, it was dichoto-
mized into <6 years and ≥6 years, the latter including those not yet infected. 
All statistical analyses were performed using SAS version 9.1 software. A 
P value of 0.05 or less was considered significant.
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